65 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dart Neuroscience
Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dart Neuroscience
Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Southern Medical University
Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Intra-Cellular Therapies
Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Mercachem
Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Southern Medical University
Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Janssen Pharmaceutica
Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Csir-Indian Institute of Integrative Medicine
Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Janssen Pharmaceutica
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Janssen-Cilag
Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Sciences
Discovery of oxazole-based PDE4 inhibitors with picomolar potency.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Monash University (Parkville Campus)
Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Biocrea
Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 1.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Synthesis and molecular modeling of novel tetrahydro-ß-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
German University In Cairo
Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Biotie Therapies
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chong Kun Dang Research Institute
Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Schering-Plough Research Institute
A new chemical tool for exploring the physiological function of the PDE2 isozyme.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Schering-Plough Research Institute
Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck
Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Sciences
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
German University In Cairo
Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shanghai Institute of Materia Medica
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Sciences
Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Mitsubishi Tanabe Pharma
Structure Overhaul Affords a Potent Purine PI3K? Inhibitor with Improved Tolerability.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
South China Agricultural University
Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Amgen
Discovery of furyl/thienyl ?-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shandong University
Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Seoul National University
Inhibitors of phosphodiesterase as cancer therapeutics.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sichuan Academy of Medical Science & Sichuan Provincial People'S Hospital
Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shandong University
Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
South China Agricultural University
Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chiesi Farmaceutici